San Rafael, CA — BioMarin Pharmaceutical Inc. today announced that it has entered into a definitive agreement to acquire Amicus Therapeutics in a transaction valued at approximately $4.8 billion, strengthening BioMarin’s position in the rare disease market and expanding its commercial and clinical portfolio.
Under the terms of the agreement, BioMarin will acquire all outstanding shares of Amicus Therapeutics, adding marketed therapies for rare genetic diseases as well as a pipeline of clinical and preclinical programs. The transaction is intended to complement BioMarin’s existing expertise in developing and commercializing treatments for underserved patient populations.
BioMarin stated that the acquisition supports its long-term strategy of sustainable growth through portfolio expansion in rare and ultra-rare conditions. Amicus’s therapies and development programs are expected to enhance BioMarin’s revenue base while providing additional opportunities for innovation in genetic and metabolic diseases.
The companies indicated that the transaction is expected to close in 2026, subject to customary closing conditions, including regulatory approvals and approval by Amicus shareholders. Following completion, Amicus will become a wholly owned subsidiary of BioMarin.
BioMarin expects the acquisition to be strategically and financially beneficial over the medium to long term, reinforcing its commitment to delivering transformative therapies to patients with serious and life-threatening rare diseases.
About BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing innovative therapies for rare genetic diseases.
About Amicus Therapeutics
Amicus Therapeutics is a biotechnology company dedicated to discovering, developing, and delivering medicines for people living with rare diseases.
By
